Mark Sabag - Feb 28, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, International Markets
Signature
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Stock symbol
TEVA
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 06:36 AM
Previous filing
Feb 9, 2023
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +20.6K +11.6% 198K Feb 28, 2023 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +50.2K +25.34% 248K Feb 28, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -20.6K -50% $0.00 20.6K Feb 28, 2023 Ordinary Shares 20.6K Direct F1, F2, F3
transaction TEVA Restricted Share Units Options Exercise $0 -50.2K -100% $0.00* 0 Feb 28, 2023 Ordinary Shares 50.2K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024.
F4 Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.